Imrecoxib tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Medicine type
- Chemical medicine
- Therapeutic area
- Musculoskeletal
- Indications recorded in the public source
- Relief of pain associated with osteoarthritis.
- Indication source and scope
- Source date(s): 2026-08-04. Manufacturer prescribing information for Mainland China.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- No additional restriction is specified for this formulary entry. General formulary rules and legally approved indications still apply.
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.imm.ac.cn/xycz/sscxyw/fa56e2c20ea44a11bc75968b350aa09e.htm
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.hengrui.com/product/innovativeMedicine.html?type=1
Open the interactive record, public price references and discussions